Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 229-175-3 | CAS number: 6422-83-9
- Acute oral toxicity: LD50(rat, m/f) > 2000 mg/kg bw; OECD TG 401; RL1; GLP
- Acute inhalation toxicity: LC50(rat, m/f) = 0.09 mg/L; OECD TG 403; RL1; GLP
- Acute dermal toxicity: LD50(rat, m/f) > 2000 mg/kg bw; OECD TG 402; RL1; GLP
Table 1: concentration measurements
Analytical concentration [mg/L]
Test group 1
Mean corrected for 1% additive
Standard deviation of the mean
Test group 2
Test group 3
Test group 4
Acute oral toxicity
In an acute oral toxicity study according to OECD guideline 401, adopted February 1987, 5 female and 5 male Wistar rats, fasted, 9 -11 weeks old were given a single dose of 2000 mg/kg bw 2,4 -Bismaleimidotoluene by gavage and were observed for 15 days. No premature death occurred during the observation period, furthermore, the body weight gain of the animals was not affected by the test article. The following clinical signs were observed: In both sexes: ruffled fur; in males hunched posture. The male rats had recovered after 7 days and the femal rats had recovered after 4 days. After the observation period the animals were sacrificied and macroscopical findings were recorded. The lungs were discolored and showed a pale appearance and the left lobe of the liver was clay-coloured in one male animal. The other animals showed no macroscopical changes. The oral LD50 in male and female Wistar rats was determined to be greater than 2000 mg/kg bw.
Based on the study results, the substance does not fulfil the criteria for classification in accordance with Regulation (EC) 1272/2008 (CLP) and the Globally Harmonized System of Classification and Labelling of Chemicals (GHS), and is thus considered to be not acutely toxic by the oral route.
Acute inhalation toxicity
In an acute inhalation toxicity study according to OECD guideline 403 (adopted May 1981), 5 female and 5 male Wistar rats per group, 8 -9 weeks old, were given 2,4 -Bismaleimodotoluene at doses of 0.016 mg/L, 0.13 mg/L, 0.52 mg/L and at the limit dose of 5 mg/L via an inhalation chamber. The animals were exposed for 4 h. After the exposure period the animals were observed for further 14 days. During the observation time the body weight was checked at the beginning of the observation time, after 7 days and at the end of the experiment. Clinical observations were mader at least once each workday and a check for dead was mase daily during the observation time. At the end of the observation time the surviving animals were sacrificed and subjected to gross pathology.
All of the animals receiving the highest dose died on application day, animals inhaling 0.52 mg/L for 4h died on experimental day one, from the female rats receiving 0.13 mg/L 2,4 -Bismaleimodotoluene for 4 h only 2 survived the experimental time. All animals inhaling the lowest dose survived. For the first 4 h after administration of the substance the animals were observed for any clinical signs. All animals regardless the applied dose of 2,4 -Bismaleimodotoluene showed restlessness and attempted to escape within the first 15 min after application. Almost all animals showed eyelid closure within the first 2h and only a few showed more severe clinical signs like intermittent respiration, whooping respiration, gasping respiration or respiratory sounds. All clinical signs were reversible within the first day after exposure. The female and male rats in group 1 (0.016 mg/L air) showed a retarded body weight gain as compared to the historical control collective, however, this decrease abolished in the second week of the observation time. Due to the occurring mortality the LC50 values were determined as follows: LC50 male/female: 0.09 mg/L; LC50 male: 0.016 to < 0.13 mg/L; LC50 female: 0.13 mg/L.
Acute dermal toxicity
In an acute inhalation toxicity study according to OECD guideline 402 (adopted February 1987), 5 female and 5 male Wistar rats, 10 -12 weeks old, were treated 2,4-Bismaleimodotoluene at a single dose of 2000 mg/kg bw applied to the skin for 24 h. During the observation period of 15 days the mortality, body weights and clinical signs like general behaviour, respiration, motility, body position, motor susceptibility and any changes of the skin, eyes or nose were recorded. At the end of the experimental time all animals underwent necropsy. No premature mortality occurred and no changes in body weight gain were determined. However, in all animals changes of the treated skin (scales and yellow skin) were detected. These effects were reversible occurred at the second day of the observation period and disappeared until at least day 10. The necropsy revealed one animal with some discoloration of the lungs. Due to the slight and fully reversible effects the dermal LD50 of 2,4 -Bismaleimidotoluene is considered to be > 2000 mg/kg bw.
Based on the available relevant and reliable data 2,4 -Bismaleimidotoluene does not need to be classified and labelled according to the CLP Regulation (EC) No 1272/2008 with respect to acute oral and dermal toxicity.
Based on the study results, the substance does fulfil the criteria for classification in accordance with Regulation (EC) 1272/2008 (CLP) and the Globally Harmonized System of Classification and Labelling of Chemicals (GHS), and is thus classified Category 2 (fatal if inhaled) with respect to inhalation toxicity and assigned the hazard statement H330 and the signal word “Danger”.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again